## ABT: Abbott Laboratories - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -4.7% below STRENGTH zone (4.0-10.0%); PEG 4.17 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($118.38)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Investment Management Corp of Ontario Sells 32,347 Shares of Abbott Laboratories $ABT**
- Source: MarketBeat | 20251209T141536 | Somewhat-Bullish | Relevance: 98%
-  Investment Management Corp of Ontario reduced its stake in Abbott Laboratories by 33.7%, selling 32,347 shares and holding 63,595 shares valued at $8.65 million. Other institutional investors also adjusted their positions in ABT. Analyst ratings for Abbott Laboratories are predominantly "Buy" or "Outperform" with a consensus price target of $147.00.

**2. Ossiam Has $8.77 Million Position in Abbott Laboratories $ABT**
- Source: MarketBeat | 20251209T122959 | Somewhat-Bullish | Relevance: 98%
-  Ossiam reduced its stake in Abbott Laboratories (NYSE:ABT) by 12.2% in the second quarter, now holding 64,496 shares valued at $8.77 million. Despite this, other institutional investors like Vanguard Group Inc. and Geode Capital Management LLC increased their positions in the healthcare product maker. Abbott Laboratories reported meeting analyst earnings expectations for the last quarter and announced a quarterly dividend, while several analysts maintain "buy" or "overweight" ratings with price targets up to $150.00.

**3. Institutional shareholders may be less affected by Abbott Laboratories' (NYSE:ABT) pullback last week after a year of 8.3% returns**
- Source: Yahoo Finance | 20251209T110736 | Neutral | Relevance: 97%
-  Institutional investors own 81% of Abbott Laboratories (NYSE:ABT), making the stock's performance sensitive to their trading actions. Despite a 4.6% drop last week, these shareholders have seen an 8.3% return over the past year, which may have softened the impact. The top 25 shareholders collectively hold less than half of the company, with The Vanguard Group, BlackRock, Inc., and Capital Research and Management Company being the largest individual institutional holders.

**4. Rep. Richard Dean Dr McCormick Has Bought Up to $390K Worth Of Abbott Laboratories Stock: Here's What You Should Know**
- Source: Benzinga | 20251210T150741 | Somewhat-Bullish | Relevance: 97%
-  Representative Richard Dean Dr McCormick purchased between $26,026 and $390,000 worth of Abbott Laboratories (NYSE: ABT) stock, with the transaction occurring on November 5, 2025, and filed in December. This transaction highlights the importance of congressional transparency regarding stock dealings. The STOCK Act of 2012 prohibits members of Congress from using private information for personal gain and mandates regular public disclosures of their financial transactions.

**5. Exact Sciences stock reaches 52-week high at 101.89 USD**
- Source: Investing.com | 20251210T161005 | Somewhat-Bullish | Relevance: 80%
- Exact Sciences Corporation (EXAS) has achieved a new 52-week stock high of $101.89, marking significant growth over the past year and six months. This surge in value is underpinned by strong investor confidence and analyst predictions of profitability, despite the stock potentially trading above its Fair Value according to InvestingPro analysis. Recent news includes Abbott Laboratories' plan to acquire Exact Sciences for approximately $23 billion, prompting several analyst downgrades to "Hold" with price targets aligning with the proposed acquisition price, expected to close by Q2 2026.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-20 | BTIG | $145 | $145 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-20 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 4 ($0.12M) |
| Sells | 1 ($0.20M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 37.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 3 |

**Top Holders:**
- Vanguard Group Inc: 10.0% (+0.2%)
- Blackrock Inc.: 8.1% (+0.2%)
- State Street Corpora: 4.5% (-0.2%)
- Capital Internationa: 3.5% (+2.5%)
- JPMORGAN CHASE & CO: 3.4% (+49.5%)

### Key Risks

1. Valuation stretched: PEG 4.2x requires aggressive growth execution.
2. Long-term trend broken: trading 5.6% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 4.17 signals overvaluation risk, limited margin of safety. Forward P/E 21.7x stretched relative to 10% growth. Quality metrics strong (ROE 31%, margin 32%). Balance sheet: $2.3B free cash flow. Institutional flow bullish (6 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $214.6B |
| Beta | 0.71 |
| 52W Range | $110.86 - $141.23 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.17 |
| Forward P/E | 21.7 |
| Current P/E | 23.9 |
| YoY Growth | 10.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 weakening modestly (-0.6% over 5 days). Below STRENGTH zone by 8.7pp (needs >4.0% for momentum thesis). MRS_5 turning positive (0.3%) - potential reversal signal. Below SMA200 (0.94x), long-term trend not supportive. RSI neutral at 41.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.67% (CS: 13) | Weak |
| RSI_14 | 40.9 | Neutral |
| MACD Histogram | -0.47 | Bearish |
| vs SMA20 | 0.975x | Below |
| vs SMA50 | 0.965x | Below |
| vs SMA200 | 0.944x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $123.28
- **Stop Loss:** $118.38 (4.0% risk)
- **Target:** $128.18 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 281
- **Position Value:** $34,641.68
- **Portfolio %:** 34.64%
- **Risk Dollars:** $1,380.00
- **Risk Per Trade:** 1.38%
- **Modifiers:** L1 115% | L2 120% | Combined 1.38x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.15x |
| L2 Sector | IGNITION (Zone D) | 1.20x |

*NORMAL regime with moderate risk appetite ahead of Fed decision. VIX at low 8th percentile signals complacency, but decent breadth and positive yield curve support selective positioning. Focus on quality names with earnings visibility.*

### Earnings

**Next:** 2026-01-21 (Est: $1.50)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $1.30 | $1.30 | +0.1% |
| 2025Q2 | $1.26 | $1.26 | +0.3% |
| 2025Q1 | $1.07 | $1.09 | +1.7% |
| 2024Q4 | $1.34 | $1.34 | -0.2% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*